Header 1: Governance Risk & Institutional Integrity
Focus: Conflicts between political oversight and regulatory independence.
1. How does the "public interest" objective in SCA s. 7 conflict with specific market efficiency mandates in CMA s. 13?
2. Could the Minister's power to appoint one-third of exchange directors (CMA s. 12) undermine the "independent" regulatory facade of SCA s. 6?
3. What is the latent risk of a "vacancy" in the Chairman position being filled by a "senior officer" under SCA s. 22(5) who lacks the statutory independence of a full appointee?
4. Does SCA s. 26 allow for an "indirect pecuniary interest" to be excused if it is not "being considered by the Commission" at that specific moment?
5. How does the "common seal" custody rule in SCA s. 5 create a single point of failure for legal authentication?
6. In what ways do the "qualified rights" under SCA s. 1 create grounds for constitutional challenges against CMA enforcement actions?
7. Does the Commission’s power to "own proprietary rights" (SCA s. 4) create a commercial conflict with its role as a neutral regulator?
8. How does the Appointment Committee's composition (SCA s. 18) ensure technical competence over political alignment?
9. What safeguards prevent the "Advisory Committee" (CDA s. 9) from becoming a lobbying arm for market participants?
10. Is the 75-year age limit in SCA s. 22 a rigid barrier or a target for tactical removals?
11. How does CMA s. 19's notice requirement for "conflict of interest" apply if the conflict is at the Commission-Board level itself?
12. Does SCA s. 11 delegation power allow for the outsourcing of core "fit and proper" assessments to private vendors?
13. What prevents the "Capital Market Development Fund" (CMA s. 428) from being used to subsidise regulatory failures?
14. How is the "casting vote" of the Chairman under SCA s. 27 audited for potential bias in split decisions?
15. Does the "good faith" indemnity in SCA s. 115 encourage regulatory overreach?
16. How does CMA s. 51 removal of directors bypass the protections in the Companies Act 1997?
17. What is the risk of the "public interest directors" (CMA s. 12) having no specific "fit and proper" criteria defined in the Act?
18. Does the Chairman's duty to "devote whole time" (SCA s. 10) preclude involvement in international standard-setting bodies?
19. How does SCA s. 20 define "unsound mind" in a way that is not prone to legal dispute?
20. Can the Commission’s "independence" be maintained if its funding relies on "sums provided by Parliament" under CMA s. 429?
21. What happens if the Appointment Committee fails to reach a quorum under SCA s. 18?
22. How does CMA s. 436 disclosure of interest for Fund Board members compare to the stricter SCA requirements?
23. Does the ability to "sue and be sued" (SCA s. 4) create a liability that necessitates a specific insurance reserve?
24. How is "neglect of duty" defined for the purpose of removing a Chairman under SCA s. 12?
25. Does the Commission have the power to regulate the "Appointment Committee" itself?
26. What is the systemic risk of the Commission acting as both "prosecutor and judge" in administrative actions under CMA s. 443?
27. How does CMA s. 23 "suspension order" affect the legal status of existing contracts if it lasts longer than 6 months?
28. Is the "Circular Resolution" power in SCA s. 28 a risk to deliberative transparency?
29. Does the "independence" in SCA s. 6 apply to the budget of the Commission or just its decisions?
30. What constitutes "unacceptable circumstances" in corporate governance under SCA s. 54?
31. How does the Commission verify "high business integrity" for exchange membership under CMA s. 9?
32. Does the "independence" of the Commission conflict with the "advice of the Minister" for staff engagement under SCA s. 36?
33. How are "public interest directors" compensated to ensure they are not "captured" by the exchange?
34. Does the Commission have a "duty of care" to the Minister under SCA s. 10?
35. What defines "serious misconduct" for the Fund Board under CMA s. 434?
36. Can the Minister override a Commission "decision" using the general power in CMA s. 455?
37. How does the Commission handle a "conflict of interest" involving the Minister?
38. What is the risk of "regulatory capture" if the Commission relies on "experts" from the industry under SCA s. 37?
39. Does the "perpetual succession" in SCA s. 4 apply if the Act is repealed without a saving provision?
40. How is the "repute of Papua New Guinea" in SCA s. 8 measured for regulatory performance?
41. What ensures the "international experience" of Commissioners under SCA s. 19 is relevant to the PNG market?
42. Does the Commission have the power to audit the "Appointment Committee"?
43. How does the "leave of absence" for the Chairman (SCA s. 13) affect the quorum for urgent decisions?
44. Can a "non-executive member" under SCA s. 16 hold a license issued by the Commission?
45. What prevents the "Chairman's report" (SCA s. 15) from being edited by the Minister before tabling?
46. How does the Commission define "integrity" for the purposes of SCA s. 19?
47. Is there a conflict between the Commission’s role in "job creation" (SCA s. 7) and "market stability"?
48. What is the risk of "Chief Executive" and "Chairman" roles being conflated under SCA s. 12?
49. How does the Commission manage "insider" risks within its own Board?
50. What is the judicial review standard for a "removal for disability" under SCA s. 12?
Header 2: Regulatory Arbitrage & Jurisdictional Gaps
Focus: Overlaps between the Commission, BPNG, and unlisted markets.
51. How does the "exempted stock market" status for BPNG-operated systems (CMA s. 8(4)) create a shadow capital market?
52. If a security is "unlisted" but "deposited," does CDA s. 3 oversight trump CMA s. 34 licensing?
53. Does the definition of "dealing" in CMA s. 2 exclude the "mere transmission" of instruments, and how is this exploited?
54. How does the "excluded offer" list in CMA Schedule 6 allow sophisticated investors to bypass prospectus protections?
55. Is there a gap in "short selling" prohibitions (CMA s. 75) for over-the-counter derivatives?
56. Does the "unit trust" definition in CMA s. 2 capture digital asset pools or tokenized real estate?
57. How do "arrangements with other supervisory authorities" (CMA s. 339) prevent information from falling through the cracks?
58. What is the arbitrage risk between "debt securities" under the Banks and Financial Institutions Act and the CMA?
59. Can an entity be a "clearing house" for derivatives (CMA s. 30) without being a "central depository" under the CDA?
60. How does the Commission resolve "conflicting directions" between it and BPNG under CMA s. 468?
61. Is a "private company" debenture issue under CMA Schedule 8 completely unregulated for market misconduct?
62. Does the "shelf registration" (CMA s. 136) allow for "zombie" prospectuses that contain stale data for derivatives?
63. How does the Commission regulate "secondary markets" for excluded offers?
64. Is there a gap in "insider trading" laws for unlisted "eligible securities" under the CDA?
65. Does the "dematerialisation date" in CDA s. 2 apply to foreign securities traded in PNG?
66. How does the Commission treat "hybrid instruments" that are both debt and derivatives under CMA s. 5?
67. What prevents a "participating organisation" from using "nominee companies" to hide beneficial ownership across acts?
68. Is the "money market" exemption in CMA Schedule 5 too broad for systemic risk monitoring?
69. How does CDA s. 43 prohibition on depository "principal trading" apply to its subsidiaries?
70. Does the Commission have jurisdiction over "offshore" derivatives offered to PNG residents under CMA s. 298?
71. What is the risk of "regulatory competition" between the SC and Registrar of Companies?
72. How is "advising on corporate finance" (CMA Schedule 2) distinguished from "legal advice" in takeovers?
73. Does the "take-over offer" definition capture "schemes of arrangement" that achieve the same control shift?
74. How does the "exempt derivatives market" (CMA s. 8) protect retail investors if "sophisticated" participants are involved?
75. Can the Commission's "power of exemption" (CDA s. 73) be used to bypass CMA conduct rules?
76. What defines "incidental" for a lawyer's exemption under CMA Schedule 3?
77. Is a "managed investment scheme" that uses a "bare trust" (CMA s. 748) subject to the same audit as a unit trust?
78. How does CDA s. 50 "notice of trust" invisibility affect the Commission’s "tracing" powers in CMA s. 407?
79. What is the systemic risk of "linkages" between depositories (CDA s. 74) if the foreign depository is unregulated?
80. Does the Commission regulate "investment advice" provided through social media under SCA s. 2 "distribute"?
81. How does the "excluded issue" list in Schedule 7 interact with CDA s. 45 "public offer" notifications?
82. Is there a gap in "prospectus liability" for information memorandums under CMA s. 125?
83. Does the Commission monitor "unsolicited offers" for unlisted products under CMA s. 151?
84. How does the "15% control" rule in CMA s. 4 interact with the "20% voting power" rule in CMA s. 416?
85. What defines a "professional investor" for the purpose of the CMA?
86. Is there a risk of "double regulation" for banks providing "custodian services" under CMA s. 98?
87. How does the Commission treat "stablecoins" under the "debt security" or "derivative" definitions?
88. Does CDA s. 17 trade restriction apply to "off-market" transfers of eligible securities?
89. What is the gap in "market manipulation" for products not traded on a "stock market" as defined?
90. How does the Commission coordinate with "foreign securities authorities" (SCA s. 2) for global derivatives?
91. Does the "repeal" of the 1997 Act (SCA s. 117) leave "fidelity fund" claims in limbo for pre-2015 events?
92. How does the Commission define "market day" (CDA s. 2) for 24/7 digital markets?
93. Is an "employee share scheme" (CMA s. 137) a loophole for insider knowledge dissemination?
94. How does the "branch register" rule (CMA s. 254) affect PNG-only tracing notices?
95. What ensures that "exempted companies" under CMA s. 117 still meet basic transparency?
96. Does the "standardised derivative" definition in CMA s. 2 exclude customised OTC swaps?
97. How does the Commission verify the "market value" of unlisted units under CMA s. 242?
98. Is there an arbitrage risk in "bonus issues" (Schedule 5) being used to bypass "listing approval" for new capital?
99. Does SCA s. 39 allow the Commission to exempt itself from any provisions?
100. How does the "33%" takeover trigger in CMA s. 276 reconcile with "substantial shareholding" at 5% in CMA s. 395?
Header 3: Enforcement & Investigation Blind Spots
Focus: Procedural gaps and unintended consequences of investigation powers.
101. Does the "forceful entry without a warrant" (SCA s. 62) expose the Commission to significant civil damages if "reasonable possibility" is not proven?
102. How does the "surrender of travel documents" (SCA s. 60) interact with the Constitutional right to liberty?
103. Is "concealing books" under SCA s. 97 enforceable against encrypted data where the "book" is a digital key?
104. Does SCA s. 64 "may not give a copy of book" prevent the Licensing Division from seeing evidence found by the Investigation Division?
105. What constitutes "unreasonable expense" for a Magistrate to destroy seized property under SCA s. 58?
106. How does the Commission ensure "natural justice" in "private" inquiries (SCA s. 74)?
107. Does the "thumb print" requirement for statements (SCA s. 66) apply to digital recordings?
108. What prevents an "Investigating Officer" from using information for personal gain given the 12-year statute of limitations in SCA s. 38?
109. How is "speedy and natural decay" determined for securities certificates under SCA s. 59?
110. Can a "stop order" under CMA s. 141 be ignored if the securities are already listed, and what is the "second-order" risk?
111. Does the "civil penalty" in CMA s. 324 require a higher "burden of proof" than administrative sanctions?
112. How does the Commission handle "privileged communications" with lawyers under CMA s. 391?
113. What defines "obstructs or hinders" under SCA s. 17 vs SCA s. 95?
114. Can the Commission "compound" an offence (SCA s. 105) that involves a victim who wants to prosecute?
115. How does the Commission monitor "Chinese Wall" effectiveness (Securities Act 1997 s. 105) without real-time surveillance?
116. Is the "standard of proof" for a takeover "pecuniary penalty" (CMA s. 292) too high for complex fraud?
117. How does the Commission verify "inadvertence or mistake" in substantial shareholding defaults under CMA s. 314?
118. What is the risk of "self-incrimination" protections (SCA s. 66) being used to stall complex investigations?
119. Does a "Magistrate's warrant" (SCA s. 61) cover cloud-hosted data outside PNG jurisdiction?
120. How does the Commission track "monies received" in trust under SCA s. 52?
121. Is the "12-year" limitation period in SCA s. 38 consistent with the Frauds and Limitations Act 1988?
122. What defines "reasonable basis" for a recommendation under CMA s. 68?
123. Can the Commission "freeze assets" of a bank under SCA s. 40 without a court order?
124. How is the "net income" levy for the Compensation Fund (CMA s. 346) verified for accuracy?
125. Does the "qualified privilege" for exchange disciplinary proceedings (Securities Act 1997 s. 26) persist under the 2015 Acts?
126. What defines "frivolous or vexatious" for beneficial ownership notices under CMA s. 135?
127. How does the Commission enforce "restraining orders" (CMA s. 281) against offshore entities?
128. Is there a "whistleblower" protection for non-listed corporation employees under CMA s. 382?
129. How does the Commission recover "investigation expenses" if the entity is insolvent (SCA s. 91)?
130. What constitutes "material incompleteness" in a filing under CMA s. 120?
131. Can the Commission require a "journalist" to disclose sources under CMA s. 63?
132. How is "recklessness" proven in "false statements" under CMA s. 301?
133. What defines "due diligence" as a defence for prospectus errors under CMA s. 146?
134. Can a "receiver" appointed under CMA s. 449 ignore existing "liens" on property?
135. How does the Commission audit "trust accounts" (SCA s. 52) for misappropriation?
136. Is "contempt of the Commission" (SCA s. 96) a criminal or civil offence?
137. How does the Commission handle "cross-border" insider trading under CMA s. 298?
138. What prevents "information leaks" from the Commission during an inquiry under SCA s. 75?
139. Can the Commission "invoice back" derivatives positions (CMA s. 444) without market disruption?
140. How is "market manipulation" intent proven under Securities Act 1997 s. 95?
141. Does "qualified privilege" (SCA s. 115) protect a Commissioner from defamation?
142. How does the Commission define "imminent danger" for an injunction under Securities Act 1997 s. 144?
143. What is the risk of "false information" being given under oath to the Commission (SCA s. 94)?
144. Can the Commission "search any person" (SCA s. 56) without a specific suspicion of a crime?
145. How does the Commission verify "parity of information" for unlisted securities under CMA s. 322?
146. What ensures that "compound" monies (SCA s. 105) are paid into the correct fund?
147. Can the Commission "reprimand" an entity (CMA s. 443) without a public hearing?
148. How does the Commission monitor "bucketing" in real-time?
149. Is "market rigging" possible in a "dark pool" electronic facility under CMA s. 27?
150. What constitutes "unacceptable corporate governance" for an investigation trigger?
Header 4: Licensing-Supervision Mismatches
Focus: Disconnects between "front-gate" approval and "back-office" monitoring.
151. If a license is "deemed" granted due to delay, how is the "fit and proper" check finalised?
152. Does the Licensing Division verify "automated systems capacity" (CMA s. 13) before approval?
153. How is the "minimum financial requirement" (CMA s. 43) monitored between annual audits?
154. What constitutes "sufficient human resources" for a trade repository under CMA s. 77?
155. Can a "registered person" (CMA s. 52) bypass the "representative" license requirements?
156. How does the Commission track "material changes" in license particulars (CMA s. 54)?
157. Does the "variation of license" (CMA s. 45) require a full re-audit of the entity?
158. What is the risk of a "licensed person" acting as its own "auditor"?
159. How does the Commission supervise "outsourced" functions of a trustee under CMA s. 190?
160. Is the "K50,000 deposit" (CMA s. 46) sufficient for a fund manager with K1 billion AUM?
161. How does Licensing reconcile "associated person" disclosures with CDA beneficial ownership?
162. Can a "casual employee" (SCA s. 33) perform licensing assessments?
163. What prevents a "revoked" license holder from continuing as a "consultant"?
164. How is "educational qualification" (CMA s. 41) verified for international applicants?
165. Does the "fit and proper" criteria in CMA s. 40 include environmental or social governance records?
166. How does Supervision monitor "priority of client orders" (CMA s. 70) in high-frequency trading?
167. Is there a gap in "insurance contract" verification for licensees under CMA s. 46?
168. How does the Commission supervise "financial planning" (Schedule 2) provided by lawyers?
169. Can a "licensed person" hold a "public interest director" seat?
170. What ensures "quarterly reports" (CMA s. 17) are actually reviewed by technical staff?
171. How is "soundness of judgment" (CMA s. 40) objectively measured during licensing?
172. Does a "surrender of license" (CMA s. 57) trigger an immediate forensic audit?
173. How does the Commission supervise "venture capital" registered persons under Schedule 4?
174. What is the risk of "license jumping" where individuals move between siloed regulated activities?
175. How does the Commission handle "probationary" licenses?
176. Can a license be "transferred" (CMA s. 45) without public notice?
177. How is "competent personnel" (CDA s. 5) verified for a central depository?
178. What prevents "licensed institutions" from misusing the "registered person" status?
179. How does the Commission supervise "audio or visual" information services (CMA s. 2)?
180. Is the "fit and proper" check in CMA s. 51 applied to all senior managers or just directors?
181. How does the Commission supervise "nominee companies" of the central depository?
182. Can a "representative" work for two "license holders" simultaneously?
183. How is "character and reputation" (SCA s. 19) vetted in jurisdictions with no reciprocal enforcement?
184. What constitutes "essential business operations" during a license suspension (CMA s. 49)?
185. How does the Commission supervise "underwriters" who are not "licensed persons" (CMA s. 116)?
186. Can a "registered person" be fined under the same gravity as a "licensed person" (CMA s. 443)?
187. How does Supervision monitor "joint dealings" between employees and licensees (CMA s. 71)?
188. What ensures that "contract notes" (CMA s. 66) are issued for OTC trades?
189. How is "brokerage" reasonableness supervised under CMA s. 88?
190. Can the Commission "withdraw registration" (CMA s. 52) without a breach?
191. How does Licensing detect "undischarged bankrupts" in foreign jurisdictions?
192. Is the "fit and proper" status of "principal officers" reviewed upon a change in "controller"?
193. How does the Commission supervise "advising on corporate finance" for unlisted entities?
194. What constitutes "properly equipped premises" (CMA s. 9) in a remote work era?
195. How are "financial journalists" (CMA s. 58) monitored for "pump and dump" schemes?
196. Does Licensing require a "business continuity plan" for all capital market products?
197. How does the Commission supervise "bond pricing agencies" (Schedule 4)?
198. Can a license be renewed (CMA s. 37) if the entity is under investigation?
199. How is "discredited conduct" (CMA s. 40) defined in the absence of a conviction?
200. What is the mismatch between "auditor" independence rules in CMA s. 103 and local market size?
Header 5: Data & Information Asymmetries
Focus: Secrecy, reporting gaps, and the "Invisibility" of beneficial ownership.
201. Does CDA s. 51 "reasonable security measures" mandate encryption standards?
202. How does CMA s. 388 "production of books" apply to data held in decentralized ledgers?
203. Is "information" in CMA s. 2 broad enough to cover metadata and communication logs?
204. How does the Commission detect "structuring" to bypass the 5% substantial holding limit?
205. Can an "authorised nominee" (CDA s. 31) legally withhold the beneficial owner's identity from the issuer?
206. What is the risk of "permitted disclosures" (CDA s. 54) being used for corporate espionage?
207. How does the Commission ensure "information insiders" (CMA s. 307) do not use "supposition"?
208. Does CDA s. 41 "record of depositors" allow for real-time issuer transparency?
209. How is "material information" defined for "continuous disclosure" under CMA s. 401?
210. What defines "readily observable matter" for "generally available" info in CMA s. 309?
211. Can the Commission access "attorney-client" privileged data during a "systemic risk" event (CMA s. 337)?
212. How does the "interests register" (CMA s. 383) prevent CEOs from using proxies?
213. Is there a gap in "tracing" powers (CMA s. 407) for derivatives that reference foreign indices?
214. How does the Commission handle "false or misleading" reports to the exchange (CMA s. 458)?
215. Does the "obligation of secrecy" (SCA s. 113) prevent sharing info with the "Tax Office"?
216. How is "confidentiality" maintained during "joint investigative efforts" (SCA s. 42)?
217. Can the Commission refuse to disclose "inspection" existence (Securities Act 1997 s. 93)?
218. How does the "data recording" definition in CMA s. 58 capture ephemeral messaging apps?
219. What ensures that "auditors" report "irregularities" (CMA s. 105) without fear of dismissal?
220. How does the Commission detect "informal arrangements" acting in concert for takeovers?
221. Is the "K100 fee" for record inspection (CDA s. 41) a barrier to transparency?
222. How is "price-sensitive information" defined for OTC derivatives (CMA s. 332)?
223. Does the Commission have the "computing power" to audit "electronic facilities" (CMA s. 27)?
224. How does the "10% ownership" rule for Commissioners (SCA s. 10) prevent indirect influence?
225. Can the "Trade Repository" (CMA s. 84) share data with "law enforcement" directly?
226. What defines "material omission" in an "information memorandum" (CMA s. 125)?
227. How does the Commission monitor "financial journalists" who are also "license holders"?
228. Is there a risk of "data silos" between the "Central Depository" and "Clearing House"?
229. How is "expert consent" (CMA s. 140) verified as genuine and not coerced?
230. Can a "depositor" hide behind a "trust" if CDA s. 50 prevents trust notice?
231. How does the Commission handle "leakage" of information to "associated persons"?
232. Is "news genuine comment" (CMA s. 137) a loophole for market manipulation?
233. How does the Commission audit the "automated systems" of an exchange (CMA s. 13)?
234. Can a "listed corporation" withhold info from the "Supervision Division" by claiming it is not "material"?
235. How is "beneficial ownership" defined for "debt securities" in CDA s. 2?
236. What prevents "data alteration" in a "mechanical device" depository (CDA s. 62)?
237. How does the Commission supervise "interactive videotext" information services?
238. Can the Commission "require delivery of books" (SCA s. 100) from a "nominee"?
239. How is "unpublished price-sensitive information" tracked for corporate insiders?
240. Does the "interests register" public inspection (CMA s. 384) expose CEOs to safety risks?
241. How does the Commission verify "nationality" in the record of depositors (CDA s. 41)?
242. Is there a gap in "reporting" for derivatives that reference "exchange rates" (CMA s. 84)?
243. How does the Commission handle "privileged" info from a "liquidator" (CMA s. 391)?
244. What defines "news report" vs "advertisement" in a digital news feed?
245. Can the Commission "restrict publication" of evidence in a "public" inquiry (SCA s. 75)?
246. How does the "3-day" notice for inspection (CMA s. 738) prevent document destruction?
247. Is there a "standard" for "prospectus" diagrams and photographs (Securities Act 1997 s. 66)?
248. How does the Commission monitor "social media network" records (SCA s. 2)?
249. Can a "trade repository" refuse a "Commission request" for data (CMA s. 84)?
250. How is "soundness of judgment" verified against "accounting records"?
Header 6: Systemic Vulnerabilities & Interdependencies
Focus: Clearing, settlement, and cascade failures.
251. How does the "Guarantee Fund" (CDA s. 56) cover a systemic default of multiple participants?
252. Is the "subrogation" of the depository (CDA s. 56) effective against a bankrupt participant's "secured creditors"?
253. What is the "cascade risk" if a "settlement partner" bank (CDA s. 8) fails?
254. How does the Commission manage "systemic risk" (CMA s. 338) without a "Lender of Last Resort" power?
255. Can the "closure of an exchange" (CMA s. 20) for 5 days prevent a market panic or worsen it?
256. What is the risk of "cross-default" between the Compensation Fund and Fidelity Fund?
257. How does "termination and set-off" (CDA s. 44) affect the liquidity of remaining participants?
258. Is there a systemic risk in "central handling" (CDA s. 3) if the computer system has a total failure?
259. How does the Commission handle "economic crisis" directives under CMA s. 20?
260. Can "unlisted debt" trading systems (Schedule 1) destabilize the main exchange?
261. How does the "Guarantee Fund" interact with the "Bank of Papua New Guinea" systems?
262. What is the risk of "realising assets" (CDA s. 44) into a falling market during an insolvency?
263. Is the "K50 million" limit for the Compensation Fund (CMA s. 348) a hard cap or a target?
264. How does the Commission monitor "margins" for OTC derivatives (CMA s. 21)?
265. What defines "financial distress" for a "significant market participant" (CMA s. 336)?
266. Can a "systemic risk" directive (CMA s. 338) bypass the right to be heard?
267. How is "financial stability" defined for coordination with the BPNG?
268. Is there a systemic risk in "under-subscriptions" (CMA s. 166) being retained?
269. How does "short selling" prohibition (CMA s. 75) affect market liquidity in a crash?
270. What prevents a "clearing house" from becoming "Too Big To Fail"?
271. How does "dematerialisation" (CDA s. 24) affect "proof of ownership" in a cyber-attack?
272. Is the "14-day" certificate delivery rule (CDA s. 19) a risk to "T+2" settlement?
273. How does the Commission manage "emergency" automated system rules (CMA s. 13)?
274. Can the "Capital Market Development Fund" be used for "bailouts"?
275. What is the risk of "foreign linkages" (CDA s. 74) causing contagion from overseas markets?
276. How is "insolvency" defined for a "registered scheme" (CMA s. 2)?
277. Can a "fidelity fund" levy (CMA s. 349) cause a participant to fail?
278. How does "immobilisation" (CDA s. 2) affect "real property" backed securities?
279. What defines "orderly functioning" of the capital market (CMA s. 336)?
280. How is "public confidence" measured for systemic risk triggers?
281. Can the Commission "modify trading hours" (CMA s. 21) for global products?
282. How does the "Guarantor" duty (CMA s. 167) manage systemic credit risk?
283. Is there a risk in "standardised agreements" for derivatives (CMA s. 2) being mispriced?
284. How does "physical stock count" (CDA s. 34) reconcile with "dematerialised" records?
285. Can "unlisted deposited securities" (CDA s. 2) be used as "systemic" collateral?
286. How does the Commission monitor "contingent liabilities" of the depository?
287. Is the "T+3 market days" for record issuance (CDA s. 41) too slow for crisis management?
288. How does "lien over unpaid securities" (CDA s. 42) affect settlement finality?
289. What defines "emergency" for the purposes of the CDA?
290. Can the Commission "direct a clearing house" (CMA s. 20) to ignore its own rules?
291. How is "liquidity" of a scheme (CMA s. 257) calculated for complex assets?
292. Is there a risk of "buy-back covenants" (CMA s. 321) draining systemic liquidity?
293. How does the Commission manage "over-the-counter" market coordination with BPNG?
294. Can "market rigging" create a "cascade" of margin calls?
295. How is "wrongful loss" (CMA s. 377) distinguished from "market loss"?
296. Is the "Compensation Fund" balance sheet (CMA s. 345) public?
297. How does "subrogation" (CMA s. 354) work if the exchange is also insolvent?
298. Can a "suspension order" (CMA s. 23) be appealed to the Minister?
299. What ensures "T+1" repayment for "call debt securities" (CMA s. 2)?
300. How does the Commission handle "settlement" of market contracts during a "closure"?
Header 7: Product Innovation & Asset Protection
Focus: Derivatives, schemes, and the safety of client property.
301. Does the "derivative" definition (CMA s. 2) cover "carbon credits" or "crypto-options"?
302. How is "client money" (CMA s. 2) segregated from "firm money" in digital wallets?
303. Is "fund management" (Schedule 2) regulated if it is "algorithmic" and not human?
304. How is the "consideration" of a derivative (CMA s. 2) valued for "unlisted" underlying assets?
305. Does "managed investment scheme" (CMA s. 2) capture "crowdfunding" ventures?
306. How are "pure risk contracts" (CMA s. 2) distinguished from "derivatives"?
307. What constitutes "safe custody" for dematerialised property under CMA s. 95?
308. Is a "custodian" (CMA s. 98) liable for "sub-custodian" failures?
309. How does the Commission verify "physical stock" of gold-backed derivatives?
310. Can "scheme property" (CMA s. 183) be "borrowed" by the trustee for its own operations?
311. How is "market value" determined for "liquid assets" in a non-liquid market?
312. Does a "trust deed" modification (CMA s. 211) allow for "fee hikes" without member consent?
313. How are "unclaimed monies" (CMA s. 270) protected from "administrative" use by the Commission?
314. Can a "trustee" avoid "due diligence" liability by "outsourcing" to an agent?
315. How are "debts and liabilities" of a client (CMA s. 94) calculated for "margin" offsets?
316. Does "client property" (CMA s. 2) include "intellectual property" used as collateral?
317. How is "suitability" of advice (Schedule 10) monitored for automated robo-advisors?
318. What defines a "willing but not anxious buyer" for unlisted unit valuation?
319. Can a "non-liquid scheme" (CMA s. 258) offer "assets" instead of "cash" for withdrawals?
320. How does the Commission regulate "stablecoin" backing assets under CMA s. 194?
321. Is "bucketing" (CMA s. 327) detectable in "off-market" derivatives?
322. How is "cornering" (CMA s. 229) defined for "thinly traded" local commodities?
323. Does "underlying" (CMA s. 2) cover "weather" or "political events"?
324. Can "client assets" be used for "stock lending" without specific consent?
325. How is "fraudulent misuse" (CMA s. 352) distinguished from "poor investment strategy"?
326. What defines "adequate provision" for complaints in a trust deed?
327. Is "hedge fund" (CMA s. 210) regulation lighter than "unit trusts"?
328. How does the Commission handle "perpetual debentures" (CMA s. 181)?
329. Can "over-subscriptions" (CMA s. 166) be kept by the issuer if the project is "cancelled"?
330. How is "misleading" defined for a "promise or forecast" (CMA s. 302)?
331. Does "dealing" include "issuing" a derivative?
332. How is "indebtedness" (CMA s. 166) verified for "digital" debentures?
333. What ensures "valuation at regular intervals" (CMA s. 191) is accurate for illiquid assets?
334. Can a "trustee" retire (CMA s. 200) if the scheme is "insolvent"?
335. How are "voting products" (CMA s. 2) defined for "DAO" structures?
336. What is the risk of "commingling" client funds in "one or more trust accounts" (CMA s. 88)?
337. Is "market price" (CMA s. 299) an objective fact in a manipulated market?
338. How is "loss avoided" (CMA s. 324) calculated for a "non-trade"?
339. Can the Commission "order disposal" of assets (CMA s. 449) without a trial?
340. How is "wrongful loss" intent (CMA s. 377) proven without a paper trail?
341. Does "expert" (SCA s. 2) include "AI" auditing models?
342. How are "foreign currency denominated debentures" (Schedule 8) supervised for FX risk?
343. Can a "managed investment scheme" use "leverage" not specified in the deed?
344. How is "significant change in business direction" (CMA s. 116) measured?
345. Is "unsolicited recommendation" (CMA s. 151) enforceable against offshore influencers?
346. How does the Commission verify "90% acceptance" for "compulsory acquisition"?
347. What defines "fair and reasonable" consideration in a takeover (CMA s. 297)?
348. Can "branch registers" (CMA s. 254) be used to bypass "PNG-only" disclosure notices?
349. How is "short selling" defined for "covered" vs "naked" positions in the CMA?
350. Is "bucket shop" activity identifiable through "trade repository" data (CMA s. 84)?
Header 8: Cross-Act & Transitional Risks
Focus: Implementation failures and "legacy" overlaps.
351. Does the "repeal" (SCA s. 117) invalidate "exemptions" granted under the 1997 Act?
352. How is "Fidelity Fund" transition (SCA s. 123) handled if liabilities exceed assets?
353. What is the status of "pending appeals" (SCA s. 119) during the 2015 transition?
354. How does the "saving" of the "Registrar" role (SCA s. 2) reconcile with the new Commission?
355. Are "previous allotments" under Securities Act 1997 s. 53 grandfathered indefinitely?
356. How does the "Takeovers Code 1998" repeal affect existing "hostile bids"?
357. What defines "transitional provisions" for "dematerialisation" (CDA s. 24)?
358. Can the Commission "modify" transitional anomalies without Parliament (SCA s. 122)?
359. How does the "Indemnity" in CMA s. 465 apply to actions taken under repealed law?
360. Is the "Fidelity Fund" (CMA s. 359) a "successor" to the 1997 Fund for all purposes?
361. How are "ongoing investigations" (SCA s. 118) transferred between procedural regimes?
362. What defines "bad faith" for actions taken under repealed law?
363. Can a "Registrar" from 1997 still exercise "perpetual" powers in SCA s. 2?
364. How does "branch register" status in the Companies Act affect CMA tracing?
365. What is the risk of "repealed act" references in existing "trust deeds"?
366. How does the Commission resolve "conflicts" between the CDA and CMA definitions of "securities"?
367. Is there a gap in "criminal prosecution" (CMA s. 464) for 1997 Act offences?
368. How is "substantial holding" calculated if shares are in "suspense" under the CDA?
369. What ensures that "forms" under the 1997 Act are still "prescribed" (SCA s. 120)?
370. Can the Commission "re-issue" a license that was "surrendered" under repealed law?
371. How does "dematerialisation" affect "bearer securities" from the 1997 era?
372. What defines "National Interest" (SCA s. 1) for the purposes of the 2015 regime?
373. How does the "3-month" report to the Minister (SCA s. 15) differ from CMA periodic reports?
374. Can "public interest directors" be removed if they were appointed under 1997 norms?
375. How does the "secrecy" rule in CMA s. 81 interact with SCA s. 106 protection of informers?
376. What ensures "international agencies" link (SCA s. 8) are not based on outdated treaties?
377. How is "expert knowledge" (SCA s. 37) defined to prevent "legacy capture"?
378. Can a "Magistrate's order" from 2014 be enforced by a 2016 "Investigating Officer"?
379. What is the status of "exempted companies" (CMA s. 171) under the new SCA objectives?
380. How is "market misconduct" under CMA Part VII applied to 2015 "transition" trades?
381. Does "unrealised loss" (CMA s. 325) apply to 1997 Act "insider" cases?
382. Can "compound" monies be applied to "Development Fund" or "Compensation Fund"?
383. How is "National Court" jurisdiction managed for cross-act appeals?
384. What defines "immaterial" contravention in CMA s. 293?
385. How does the "6-year" limit in CMA s. 446 interact with the "12-year" limit in SCA s. 38?
386. Is "wrongful loss" (CMA s. 377) applicable to conduct that was "legal" in 1997?
387. How are "material misrepresentations" (CMA s. 137) tracked across "legacy" media?
388. Can a "trade repository" be approved if it was formerly an "exempt market"?
389. How does "immobilisation" affect "pledges" created under the 1997 Act?
390. Is a "trust deed" from 1999 still "legally enforceable" (CMA s. 212)?
391. How is "fair treatment" of members (CMA s. 191) audited for 20-year-old schemes?
392. Does the Commission have the "power to review" (SCA s. 111) 1997 Act Registrar decisions?
393. How are "branch registries" outside PNG monitored for "2015 Act" compliance?
394. What constitutes "natural justice" (SCA s. 79) for a "legacy" offender?
395. Can "search warrants" (SCA s. 61) be used to find documents from the 1990s?
396. How is "market manipulation" intent (CMA s. 300) distinguished from "1997 style" arbitrage?
397. What ensures that "auditor" reports (CMA s. 380) use 2015 standards for "stale" accounts?
398. Is "insider information" (CMA s. 250) different from 1997 "inside information"?
399. How is "wrongful loss" calculated if the "National Interest" (SCA s. 1) has shifted?
400. Can the Commission "vary" a license that was "perpetual" in the 1997 era?
Header 9: Market Conduct & Takeovers Blind Spots
Focus: Insider trading, manipulation, and the mechanics of control.
401. How does "matters of supposition" (CMA s. 308) prevent "insiders" from trading on gut feeling?
402. Is "parity of information" (CMA s. 322) possible in a market with only one "stockbroker"?
403. How is "intent to induce" (CMA s. 300) proven without "direct communication"?
404. Does "acting in concert" (CMA s. 276) include "algorithmic" mirroring?
405. How are "hostile takeovers" (CMA s. 277) managed for "National Interest"?
406. Can a "dissenting shareholder" (CMA s. 295) stop an acquisition via a "suspense" order?
407. What constitutes "unacceptable circumstances" for a "restraining order" (CMA s. 281)?
408. How is "material effect" (CMA s. 310) measured for an illiquid security?
409. Does "insider trading" apply to "unit trust" buy-backs (CMA s. 321)?
410. How does the Commission detect "wash trades" (CMA s. 299) in "registered facilities"?
411. Can "fictitious transactions" (CMA s. 299) be hidden via "cross-border" derivatives?
412. How is "control" (CMA s. 276) calculated if voting shares are "jointly held"?
413. What defines "inducement" in a "financial planning" recommendation?
414. Can "takeover" rulings (CMA s. 277) be appealed if they are not in the "National Gazette"?
415. How does the Commission verify "90% nominal value" for acquisitions in "nominee" names?
416. Does "insider" knowledge include "intent to make a takeover"?
417. How is "wrongful loss" (CMA s. 377) proven for a "omission to act"?
418. Can "short selling" prohibitions be bypassed via "swap agreements" (CMA s. 2)?
419. How does the Commission monitor "market rigging" for "unlisted debt"?
420. What ensures "equal opportunity" (CMA s. 277) in a partial bid?
421. Is "insider trading" enforceable for "commodities" derivatives?
422. How is "reckless publishing" (CMA s. 302) distinguished from "bad research"?
423. Can the Commission "order liquidation" (CMA s. 21) of a takeover position?
424. How is "material misrepresentation" (CMA s. 137) tracked in sound recordings?
425. What constitutes "informal understanding" for concert parties?
426. Can a "minority shareholder" (CMA s. 296) force a buy-back if the price has crashed?
427. How does the Commission detect "bucketing" in "over-the-counter" trades?
428. Is "cornering" (CMA s. 329) possible for "virtual" assets?
429. How is "gain made" (CMA s. 324) calculated for an insider who "tipped" but didn't trade?
430. Does "dealing" include "agreeing to deal" (CMA s. 2)?
431. How is "generally available" info defined for a "closed" user group?
432. Can "manipulative devices" (CMA s. 303) include AI "front-running"?
433. How does the Commission track "assignment of rights" (CMA s. 375) for insiders?
434. What defines "oppressive practice" for licensing refusal (CMA s. 40)?
435. How is "due diligence" proven for a "verbal" recommendation?
436. Can the Commission "stay civil actions" (Securities Act 1997 s. 179) during a takeover?
437. How is "net consideration" (CMA s. 138) verified for asset-swap offers?
438. Does "prohibit trading" (CMA s. 21) apply to "non-bearer" securities in the CD?
439. How is "unauthorised use of material" (SCA s. 93) tracked internally?
440. Can a "stop order" (CMA s. 141) be issued against a "replacement prospectus"?
441. How is "loss avoided" (CMA s. 324) measured for "hedged" positions?
442. Does "associated person" (CMA s. 3) include "civil partners"?
443. How are "contract note" requirements (CMA s. 66) enforced for "mobile" trades?
444. Can the Commission "order restitution" (CMA s. 443) for "unrealised" losses?
445. How is "market integrity" (CMA s. 19) reconciled with "political" interests?
446. What defines "efficient allocation of resources" (Securities Act 1997 s. 146)?
447. How is "wrongful loss" proven if the "victim" is a corporate entity?
448. Can "takeover rulings" (CMA s. 277) be bypassed via "private treaty"?
449. How does the Commission monitor "supposition" in "investment reports"?
450. Is "contempt" (SCA s. 96) applicable to a "refusal to speak" under SCA s. 66?
Header 10: Compensation & Recovery Mechanics
Focus: Funds, subrogation, and the "Cost of Justice".
451. Is the "K10 million" limit for a "civil penalty" (CMA s. 324) indexed for inflation?
452. How does the "Compensation Fund" (CMA s. 341) handle "unclaimed" payout balances?
453. Does "subrogation" (CMA s. 354) apply to "interest" and "legal costs"?
454. How is "monetary loss" (CMA s. 352) distinguished from "speculative loss"?
455. What ensures that "compound" fees (SCA s. 105) aren't used to "buy off" scrutiny?
456. Can the Commission recover " damages for negligence" (SCA s. 84) on behalf of a "class"?
457. How are "restitution" payouts (CMA s. 443) prioritized among competing victims?
458. Does the "Development Fund" objectives (CMA s. 430) allow for "legal aid" to victims?
459. How is "unclaimed money" (CMA s. 270) valued if the "property" is illiquid?
460. Is there a "statute of limitations" for a "fidelity fund" claim (CMA s. 359)?
461. Can the Commission "charge a 10% commission" (SCA s. 52) on compensation funds?
462. How is "wrongful loss" (CMA s. 377) valued for "non-monetary" assets?
463. What ensures that "insurance contracts" (CMA s. 356) cover "cyber-theft"?
464. How does the Commission handle "insolvency" of the Compensation Fund itself?
465. Can "costs of investigation" (SCA s. 91) be recovered from a "whistleblower"?
466. How are "pecuniary gain" values (CMA s. 324) calculated for "barter" trades?
467. Is "civil liability" (CMA s. 446) limited by "corporate veil" protections?
468. How is "actual pecuniary loss" (Securities Act 1997 s. 40) defined in 2015?
469. Can the Commission "sell property" (SCA s. 58) to pay investigation debts?
470. What ensures "fair representation" in Fund Board quorum (CMA s. 435)?
471. How is "restitution" monetary payment (CMA s. 281) recovered as a "civil debt"?
472. Does "defalcation" (CMA s. 352) cover "accidental" data loss?
473. How is "compensation" distribution (CMA s. 1714) audited for fairness?
474. Can the Commission "retain" undistributed funds indefinitely (CMA s. 324)?
475. How does "subrogation" affect a victim's "tax loss" claims?
476. What is the risk of "double recovery" between the CDA and CMA funds?
477. Can the Commission "direct repayment" (CMA s. 164) without a court order?
478. How is "loss avoided" measured for an insider who "hedged" but didn't sell?
479. Does "wrongful loss" (CMA s. 377) trigger the Compensation Fund?
480. How are "donations and gifts" (CMA s. 429) vetted for "influence" risk?
481. Can the Commission "invest" the Fund in the very market it regulates?
482. How is "malice" proven to bypass "good faith" indemnity (SCA s. 115)?
483. What defines "reasonable public notice" for recovery claims?
484. Can "unclaimed or undistributed money" (CMA s. 270) be used for "staff training"?
485. How is "compensation" for "neglect of duty" (SCA s. 12) sought?
486. Does "civil liability" (CMA s. 144) cover "emotional distress" from losses?
487. How is "gross amount" (CMA s. 324) defined for tax purposes?
488. Can a "Magistrate" order the Commission to "repay" seizing costs?
489. What constitutes "fair print" certification for Act authenticity?
490. How is "wrongful loss" distinguished from "unlucky investment"?
491. Can the "Fund Board" (CMA s. 431) be sued for "poor investment" of the Fund?
492. How is "restitution" calculated for "loss of opportunity"?
493. Does the "12-year" limit (CMA s. 324) override the "6-year" contract limit?
494. How is "malice" proven for an "auditor" default (CMA s. 172)?
495. Can the Commission "withdraw" an approved "restitution" plan?
496. How are "court costs" (Securities Act 1997 s. 145) recovered as a debt?
497. Does "subrogation" apply if the "insurer" is insolvent?
498. How is "restitution" managed for "joint and several" liability?
499. Can the "Development Fund" (CMA s. 428) be dissolved by the Minister?
500. How does the Commission ensure "unclaimed property" (CMA s. 270) is not "lost" in the transition?